Parexel mounts a share buyback; WuXi uses its Harvard ties;

> Parexel ($PRXL) is setting aside $200 million to buy back 2.3 million of its own shares in what CEO Josef von Rickenbach said is "an important step toward continuing to optimize the capital structure of the company." More

> WuXi PharmaTech's ($WX) Harvard ties helped it land a big genomics partnership in China. News

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.